{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:49Z","timestamp":1790179669971,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1166-z","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T07:33:18Z","timestamp":1479454398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24\u00a0weeks after initiation of rituximab treatment in rheumatoid arthritis patients"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-4929","authenticated-orcid":false,"given":"Stefan","family":"Bruijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tsang-A-Sjoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennie","family":"Raterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ramwadhdoebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Peter","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny","family":"van der Laken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"1166_CR1","first-page":"350(25)","volume":"17","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;17:350(25).","journal-title":"N Engl J Med"},{"issue":"11","key":"1166_CR2","first-page":"2109","volume":"32","author":"J Higashida","year":"2005","unstructured":"Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32(11):2109\u201315.","journal-title":"J Rheumatol"},{"issue":"10041","key":"1166_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","volume":"388","author":"D Porter","year":"2016","unstructured":"Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239\u201347.","journal-title":"Lancet"},{"issue":"9","key":"1166_CR4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1166_CR5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","volume":"71","author":"PP Tak","year":"2012","unstructured":"Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71(3):351\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1166_CR6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01731847","volume":"23","author":"T Jones","year":"1996","unstructured":"Jones T. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med. 1996;23(2):207\u201311.","journal-title":"Eur J Nucl Med"},{"key":"1166_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-015-0770-7","volume":"17","author":"YY Gent","year":"2015","unstructured":"Gent YY, Ter Wee MM, Voskuyl AE, den Uyl D, Ahmadi N, Dowling C, et al. Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Res Ther. 2015;17:266.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1166_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.30655","volume":"64","author":"YYJ Gent","year":"2012","unstructured":"Gent YYJ, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BAC, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum. 2012;64(1):62\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1166_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2967\/jnumed.110.076711","volume":"52","author":"EH Elzinga","year":"2011","unstructured":"Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, et al. 18\u00a0F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011;52(1):77\u201380.","journal-title":"J Nucl Med"},{"issue":"3","key":"1166_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-012-2282-x","volume":"40","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, Hautaniemi S, Mottonen T, Nuutila P, Oikonen V, Parkkola R, et al. Correlation of 18\u00a0F-FDG PET\/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging. 2013;40(3):403\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1166_CR11","first-page":"18","volume":"59","author":"GA Dongen van","year":"2015","unstructured":"van Dongen GA, Huisman MC, Boellaard R, Harry HN, Windhorst AD, Visser GW, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging. 2015;59(1):18\u201338.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"4","key":"1166_CR12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","volume":"5","author":"MJ Vosjan","year":"2010","unstructured":"Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5(4):739\u201343.","journal-title":"Nat Protoc"},{"issue":"8","key":"1166_CR13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","volume":"42","author":"K Muylle","year":"2015","unstructured":"Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, et al. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42(8):1304\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1166_CR14","doi-asserted-by":"crossref","unstructured":"Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int. 2014;2014:1\u201314.","DOI":"10.1155\/2014\/681678"},{"issue":"3","key":"1166_CR15","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar2686","volume":"11","author":"B Moller","year":"2009","unstructured":"Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R62.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1166_CR16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1166_CR17","first-page":"1271","volume":"44","author":"I Verel","year":"2003","unstructured":"Verel I, Visser GW, Boellaard R, Stigter-van WM, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44(8):1271\u201381.","journal-title":"J Nucl Med"},{"issue":"2","key":"1166_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.113.130112","volume":"55","author":"NE Makris","year":"2014","unstructured":"Makris NE, Boellaard R, Visser EP, de Jong JR, Vanderlinden B, Wierts R, et al. Multicenter harmonization of 89Zr PET\/CT performance. J Nucl Med. 2014;55(2):264\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"1166_CR19","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1136\/annrheumdis-2012-201540","volume":"71","author":"MJ Hair de","year":"2012","unstructured":"de Hair MJ, Zijlstra IA, Boumans MJ, van de Sande MG, Maas M, Gerlag DM, et al. Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Ann Rheum Dis. 2012;71(11):1911\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1166_CR20","doi-asserted-by":"crossref","first-page":"R862","DOI":"10.1186\/ar1757","volume":"7","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther. 2005;7(4):R862\u20137.","journal-title":"Arthritis Res Ther"},{"key":"1166_CR21","doi-asserted-by":"crossref","unstructured":"van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34\u201340","DOI":"10.1002\/art.1780390105"},{"key":"1166_CR22","doi-asserted-by":"crossref","unstructured":"Jauw YWS, Huisman MC, De Jong D, Vugts DJ, Zweegman S, Van Dongen GAMS, et al. 89Zr-labeled-rituximab PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma. [Abstract] 6th international workshop on PET in lymphoma, Palais de l'Europe, Menton (France); 2016.","DOI":"10.1371\/journal.pone.0169828"},{"issue":"4","key":"1166_CR23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619\u201324.","journal-title":"Ann Oncol"},{"issue":"3","key":"1166_CR24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72(3):329\u201336.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T15:09:00Z","timestamp":1568560140000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1166-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1166-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]},"article-number":"266"}}